We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 236% below its sector, cheaper than its peers on earnings.
Sinew Pharma Inc. is a biopharmaceutical enterprise dedicated to the research, development, and commercialization of new therapeutics. Its core mission revolves around pioneering innovative solutions for hepatotoxicity-free acetaminophen and addressing various fatty liver conditions. The company's robust pipeline features SNP-610, a drug candidate currently advancing through Phase II clinical trials in Taiwan for the treatment of non-alcoholic steatohepatitis (NASH). Another early-stage compound, SNP-630, is also in preclinical development, targeting NASH. Beyond liver disease, Sinew Pharma is progressing SNP-810 for its analgesic and antipyretic properties. Furthermore, the firm is developing SNP-830 and SNP-840, positioned as liver-safe pain medications specifically for the United States market. Established in 2014, Sinew Pharma Inc. maintains its headquarters in Taipei City, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6634.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
